# Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery

> **NCT06214533** · NA · UNKNOWN · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Liver, Cancer of, Primary Resectable

## Interventions

- **DRUG:** Ropivacaine 0.5%
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT06214533
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-01
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06214533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06214533, "Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06214533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*